Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Familial dyslipidemias of either heterozygous (heFH) or combined (FCH) type lead to accelerated atherogenesis and increased cardiovascular risk. OBJECTIVE: The aim of this study was to investigate in statin-naïve adult patients with familial dyslipidemias whether inflammatory activation and liver, spleen and bone marrow metabolic activity differ compared with normolipidemic subjects and between dyslipidemic groups. METHODS: Fourteen patients with FCH, 14 with heFH, and 14 normolipidemic individuals were enrolled. Serum lipids, high-sensitivity C-reactive protein, and fibrinogen levels were measured, followed by 18F-fluorodeoxyglucose positron-emission tomography/computed tomography imaging. Radiotracer uptake in the aortic wall, spleen, bone marrow, and liver was quantified as tissue-to-background ratio (TBR). RESULTS: Patients with heFH had significantly higher low-density lipoprotein levels compared with those with FCH and controls (P 

Original publication

DOI

10.1016/j.jacl.2017.10.019

Type

Journal article

Journal

J Clin Lipidol

Publication Date

2018

Volume

12

Pages

33 - 43

Keywords

(18)FDG PET/CT, Bone marrow, Familial dyslipidemias, Spleen, Vascular inflammation, Adult, Biomarkers, Bone Marrow, C-Reactive Protein, Case-Control Studies, Female, Heterozygote, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hyperlipidemia, Familial Combined, Hyperlipoproteinemia Type II, Inflammation, Lipoproteins, LDL, Liver, Male, Middle Aged, Positron Emission Tomography Computed Tomography, Spleen